Enhancing interaction between CNS lymphoma and therapeutic cells (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Enhancing interaction between CNS lymphoma and therapeutic cells (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A3079 1994. Unique Identifier : AIDSLINE ICDB/95604764
Lampson L; Ghogawala Z; Chen A; Kim L; Jenkins J; Dept. of Neurology, Harvard Medical School, Boston MA 02115

Abstract: CNS lymphoma, the major AIDS-associated malignancy of the nervous system, has a characteristic growth pattern. Tumor appears in the perivascular spaces, and infiltrates brain parenchyma. New therapies, and improved delivery to infiltrative tumor, are both needed. We are defining how inflammatory cells can be made to enter and move through the brain. Different leukocyte populations are of therapeutic interest in their own right, and also as vehicles for delivery of drugs, retroviral vectors, or other agents. Few leukocytes are found in normal brain. Here we describe how leukocytes can be made to enter and move through the brain, to increase their contact with tumor with the distribution of CNS lymphoma. Methods: Tumor cell lines are made to express the lacZ reporter gene. Histochemical stain for the lacZ gene product permits identification of infiltrating tumor cells in tissue sections. Antibody staining permits identification of inflammatory cells on the same slides. Computer-assisted image analysis permits quantitative study of tumor growth and tumor/leukocyte interactions. Cytokines are injected stereotactically into the rat brain. Results: A single injection of gamma interferon (IFN-g) causes monocytes, T cells, and NK cells to accumulate in the perivascular spaces in the injection hemisphere. Monocytes and NK cells, but few T cells, also migrate through the parenchyma. T cell migration is increased in rats that have been immunized to a neural antigen. Discussion: Cytokines can increase the efficiency with which leukocytes enter the brain, and move to sites of CNS lymphoma. The cells may themselves attack tumor, or may deliver other therapeutic agents.

Keywords: Brain Neoplasms/IMMUNOLOGY/*THERAPY Human *Immunotherapy, Adoptive Interferon Type II/PHARMACOLOGY/*THERAPEUTIC USE Killer Cells, Lymphokine-Activated/DRUG EFFECTS/*IMMUNOLOGY Killer Cells, Natural/DRUG EFFECTS/*IMMUNOLOGY Lymphocyte Transformation Lymphoma/IMMUNOLOGY/*THERAPY T-Lymphocytes/IMMUNOLOGY ABSTRACT
950330
M9530833

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .